Novartis Breast Cancer Drug Shows Promising Results in Clinical Trial

Key Takeaways

• Novartis’ Kisqali breast cancer drug demonstrated longer success rates for certain forms of the disease.
• In a Phase 3 clinical trial, Kisqali combined with endocrine therapy (ET) reduced the risk of recurrence by nearly 30% compared to ET alone.
• Novartis expects the FDA to make a decision on the approval of the treatment this quarter.

American depositary receipts (ADRs) of Novartis (NVS) gained momentum on Monday as new research revealed promising results for the company’s breast cancer treatment, Kisqali.

Novartis reported an updated analysis of a Phase 3 clinical trial of Kisqali combined with endocrine therapy (ET). The analysis found that the treatment produced a “deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5%” for patients with stage II or III HR+/HER2- early breast cancer compared to ET alone.

Dr. Peter Fasching, a trial investigator, emphasized the significant risk of cancer recurrence for patients diagnosed with this form of breast cancer. He stated that clinicians have been actively searching for ways to address this issue. The results of the study are particularly important because they include a broad range of patients at risk of recurrence who are in need of new treatment options to reduce that risk.

Novartis Expects FDA Decision This Quarter

Novartis has submitted the results of the clinical trial to the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) last year. The company anticipates FDA regulatory action on the approval of the treatment to be made this quarter.

Novartis ADRs experienced a 1% increase, reaching $116.61 soon after the opening bell on Monday. Although they have slightly declined since hitting an all-time high last month, they are still up 15% this year.

These findings bring hope to breast cancer patients and their healthcare providers. Kisqali has the potential to significantly improve outcomes and reduce the risk of recurrence for patients with stage II or III HR+/HER2- early breast cancer. The drug’s ability to produce longer success rates beyond the three-year treatment period is a promising development in the fight against breast cancer.

Novartis’ dedication to advancing cancer treatments is evident in its commitment to conducting rigorous clinical trials and submitting the results to regulatory authorities. The company’s collaboration with the FDA and EMA demonstrates its commitment to bringing effective treatments to market.

Investors have responded positively to the news, as reflected in the increase in Novartis ADRs. This indicates confidence in the potential success of Kisqali and the positive impact it could have on Novartis’ financial performance.

As Novartis awaits the FDA’s decision, breast cancer patients and healthcare professionals eagerly anticipate the availability of Kisqali as a potential treatment option. If approved, Kisqali could provide a new level of hope and improved outcomes for patients facing the risk of cancer recurrence.

It is important to note that while the results of the Phase 3 clinical trial are promising, further research and analysis are required to fully understand the long-term benefits and potential side effects of Kisqali. Healthcare professionals will continue to closely monitor the drug’s performance and assess its impact on patient outcomes.

In conclusion, Novartis’ Kisqali breast cancer drug has shown promising results in a Phase 3 clinical trial. The treatment, when combined with endocrine therapy, has demonstrated a significant reduction in the risk of recurrence for patients with stage II or III HR+/HER2- early breast cancer. Novartis expects the FDA to make a decision on the approval of the treatment this quarter. The positive findings bring hope to breast cancer patients and highlight Novartis’ commitment to advancing cancer treatments.

Read the original article on Investopedia.